I am working on a story on companies focusing on exercise mimetics as a target in their anti-obesity assets. I am looking to better understand the broader clinical and market context around muscle biology in obesity and weight loss, particularly in relation to existing therapies such as GLP-1s, as well as the evidence requirements for newer approaches in this space. Looking for analysts and researchers who can shed light on this.

I've worked with muscle markers like myostatin and creatine kinase. Tracking these showed us exactly what was happening during weight loss, especially with GLP-1s. It was tricky to monitor exercise mimetics at first, but it helped us see how people recover. If I were designing these trials, I would track muscle strength and signaling over time, not just fat loss. People want to stay strong, not just see a lower number on the scale. If you have any questions, feel free to reach out to my personal email